John T Isaacs
Overview
Explore the profile of John T Isaacs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
133
Citations
5821
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumar R, Jonnatan S, Sanin D, Vakkala V, Kadam A, Kumar S, et al.
medRxiv
. 2024 Dec;
PMID: 39711733
Supraphysiological androgen (SPA) treatment can paradoxically restrict growth of castration-resistant prostate cancer with high androgen receptor (AR) activity, which is the basis for use of Bipolar Androgen Therapy (BAT) for...
2.
Nouri M, Varkaris A, Ridinger M, Dalrymple S, Dennehy C, Isaacs J, et al.
Mol Cancer Ther
. 2024 Jun;
23(10):1404-1417.
PMID: 38894678
Polo-like kinase 1 (PLK1) inhibitors have had limited antitumor efficacy as single agents, and focus of current efforts is on combination therapies. We initially confirmed that the PLK1-specific inhibitor onvansertib...
3.
Jasmine S, Mandl A, Krueger T, Dalrymple S, Antony L, Dias J, et al.
Prostate
. 2024 Apr;
84(10):909-921.
PMID: 38619005
Introduction: Lysine-specific demethylase 1 (LSD1) is emerging as a critical mediator of tumor progression in metastatic castration-resistant prostate cancer (mCRPC). Neuroendocrine prostate cancer (NEPC) is increasingly recognized as an adaptive...
4.
Labrecque M, Brown L, Coleman I, Nguyen H, Dalrymple S, Brennen W, et al.
Prostate
. 2023 Oct;
84(1):100-110.
PMID: 37796107
Background: Androgen receptor (AR) pathway inhibition remains the cornerstone for prostate cancer therapies. However, castration-resistant prostate cancer (CRPC) tumors can resist AR signaling inhibitors through AR amplification and AR splice...
5.
Isaacs J, Dalrymple S, Antony L, Marc Rosen D, Coleman I, Nelson P, et al.
Prostate
. 2023 Aug;
83(15):1470-1493.
PMID: 37559436
Background: The quinoline-3-carboxamide, Tasquinimod (TasQ), is orally active as a maintenance therapy with an on-target mechanism-of-action via allosteric binding to HDAC4. This prevents formation of the HDAC4/NCoR1/HDAC3 complex, disrupting HIF-1α...
6.
Isaacs J
Am J Clin Exp Urol
. 2023 Jul;
11(3):194-205.
PMID: 37441442
During mammalian evolution, circulating levels of gonadotropins [i.e., luteinizing hormone (LH) and follicle-stimulating hormone (FSH)] acquired regulation by environmental (e.g., light, temperature, water, food, predators, etc.), and social (e.g., sound,...
7.
Lawrence M, Taylor R, Cuffe G, Ang L, Clark A, Goode D, et al.
Nat Rev Urol
. 2023 Jan;
20(6):371-384.
PMID: 36650259
Patient-derived xenografts (PDXs) are generated by engrafting human tumours into mice. Serially transplantable PDXs are used to study tumour biology and test therapeutics, linking the laboratory to the clinic. Although...
8.
Patterson J, Varkaris A, Croucher P, Ridinger M, Dalrymple S, Nouri M, et al.
Cancer Res
. 2022 Nov;
83(2):219-238.
PMID: 36413141
Significance: Abiraterone treatment induces mitotic defects that sensitize cancer cells to Plk1 inhibition, revealing an AR-independent mechanism for this synergistic combination that is applicable to a variety of cancer types.
9.
Sena L, Kumar R, Sanin D, Thompson E, Rosen D, Dalrymple S, et al.
J Clin Invest
. 2022 Oct;
132(23).
PMID: 36194476
Testosterone is the canonical growth factor of prostate cancer but can paradoxically suppress its growth when present at supraphysiological levels. We have previously demonstrated that the cyclical administration of supraphysiological...
10.
Sena L, Brennen W, Isaacs J
Nat Cancer
. 2022 May;
3(5):530-531.
PMID: 35624340
No abstract available.